

RNF213-associated urticarial lesions with hypercytokinemia

Camille Louvrier, Fawaz Awad, Anne Cosnes, Elma El Khouri, Eman Assrawi, Aphrodite Daskalopoulou, Bruno Copin, Hélène Bocquet, Sandra Chantot Bastaraud, Angela Arenas Garcia, et al.

▶ To cite this version:

Camille Louvrier, Fawaz Awad, Anne Cosnes, Elma El Khouri, Eman Assrawi, et al.. RNF213-associated urticarial lesions with hypercytokinemia. Journal of Allergy and Clinical Immunology, 2022, Online ahead of print. 10.1016/j.jaci.2022.06.016. inserm-03776857

HAL Id: inserm-03776857 https://inserm.hal.science/inserm-03776857

Submitted on 14 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

- 1 RNF213-associated urticarial lesions with hypercytokinemia
- 2
- 3 Authors: Camille Louvrier PharmD PhD^{1,2}*, Fawaz Awad MD PhD^{1‡*}, Anne Cosnes MD^{3*},
- 4 Elma El Khouri PhD¹, Eman Assrawi MD PhD¹, Aphrodite Daskalopoulou MSc¹, Bruno
- 5 Copin MSc^{1,2}, Hélène Bocquet MD³, Sandra Chantot Bastaraud MD², Angela Arenas Garcia
- 6 MSc¹, Florence Dastot Le Moal PhD², Pierre De La Grange PhD⁴, Philippe Duquesnoy MSc¹,
- 7 Chiara I. Guerrera PhD⁵, William Piterboth BSc², Nicolas Ortonne MD PhD⁶, Olivier
- 8 Chosidow MD PhD^{3,7§}, Sonia A. Karabina PhD^{1§}, Serge Amselem MD PhD^{1,2**}, Irina
- 9 Giurgea MD PhD^{1,2}**
- 10

11 AFFILIATIONS

- ¹² ¹Sorbonne Université, Inserm, Childhood Genetic Disorders, Hôpital Armand-Trousseau,
- 13 75012 Paris, France
- ¹⁴ ²Département de Génétique Médicale, Assistance Publique–Hôpitaux de Paris (APHP),
- 15 Hôpital Armand-Trousseau, 75012 Paris, France
- ¹⁶ ³Faculté de Santé de Créteil et Service de Dermatologie, APHP, Hôpital Henri-Mondor,
- 17 Université Paris-Est, 94000 Créteil, France
- ⁴GenoSplice, 75014 Paris, France
- ¹⁹ ⁵Plateforme protéomique Necker, Université de Paris, Structure Fédérative de Recherche
- 20 Necker, Inserm US24/CNRS UMS3633, 75015 Paris, France
- ⁶Département d'Anatomo-Pathologie, APHP, Hôpital Henri-Mondor, Créteil 94000, France
- ²² ⁷Research Group Dynamic, EA7380, Faculté de Santé de Créteil, Ecole Nationale Vétérinaire
- 23 d'Alfort, USC ANSES, Université Paris-Est Créteil, 94000 Créteil, France
- ²⁴ [‡]Present address: Al-Quds University, Faculty of Medicine, Biochemistry and Molecular
- 25 Biology Department; Abu Deis, Jerusalem, Palestine
- 26
- 27 *These authors contributed equally to this work.
- ⁸These authors contributed equally to this work.
- 29 **These authors contributed equally as co-last authors.
- 30
- 31 Correspondence to: Irina Giurgea and Serge Amselem, UMR_S933 Inserm, Sorbonne
- 32 Université, Hôpital Armand Trousseau, 26, avenue du Dr. Arnold-Netter, 75012 Paris,
- 33 France; Tel.: +33 1 44 73 52 39; Fax: +33 1 44 73 52 19; Email: <u>irina.giurgea@inserm.fr</u>;
- 34 <u>serge.amselem@inserm.fr</u>

35

36 FUNDING

- 37 Institut National de la Santé et de la Recherche Médicale (INSERM) and Sorbonne University
- 38 Agence Nationale de la Recherche (ANR-17-CE17-0021-01)
- 39 H2020, European Union, Grant Agreement no. 779295 (SAK, SA)
- 40 INSERM "Poste d'accueil" program (00552404) (CL)
- 41 "Fondation pour la Recherche Médicale" (FDT20130928419) (FA)
- 42 French government grant (Ministère des Affaires Etrangères) (FA, EA)
- 43 Alquds University grant, Palestine (FA)
- 44 An-Najah University grant, Palestine (EA)
- 45
- 46

- 47 ABSTRACT
- 48

Background. Urticarial lesions are observed in both cutaneous and systemic disorders. Familial
 forms of urticarial syndromes are rare and can be encountered in systemic auto-inflammatory
 diseases.

52 **Objective.** We investigated a large family with dominantly inherited chronic urticarial lesions 53 associated with hypercytokinemia.

- 54 **Methods.** We performed a genetic linkage analysis in 14 patients from a 5-generation family, 55 as well as whole-exome sequencing, cytokine profiling and transcriptomic analyses on samples 56 from two patients. The identified candidate protein was studied after *in vitro* expression of the 57 corresponding normal and mutated recombinant proteins. An unsupervised proteomic approach 58 was followed to unveil the associated protein network.
- 59 **Results.** The disease phenotype of the most affected family members is characterized by chronic urticarial flares associated with extremely high plasma levels of pro- (IL-1β, IL-6, TNF-60 α) and anti-inflammatory (IL-10, IL1-RA) cytokines, with no secondary organ dysfunction, no 61 62 susceptibility to infections, no fever and normal C-reactive protein levels. Monocyte transcriptomic analyses identified an immunotolerant profile in the most affected patient. 63 Affected family members carried a loss-of-function mutation in RNF213 that encodes mysterin, 64 a protein of poorly known physiological role. We identified the deubiquitinase CYLD, a major 65 regulator of inflammation, as an RNF213 partner and showed that CYLD expression is inhibited 66 by wild-type but not mutant RNF213. 67
- 68 **Conclusion.** We identified a new entity characterized by chronic urticarial lesions associated 69 with a clinically-blunted hypercytokinemia. This disease, due to a loss of function of RNF213, 70 reveals mysterin's key role in the complex molecular network of innate immunity.
- 71

72 KEY MESSAGES

- We describe a new disease entity, characterized by urticarial lesions that segregate as a
 fully penetrant autosomal-dominant trait associated with a chronic and clinically
 blunted hypercytokinemia.
- The obtained genetic and functional data reveal the critical role played by RNF213 in
 innate immunity.
- 78

79 CAPSULE SUMMARY

A germline mutation in *RNF213*, a new player in innate immunity encoding a protein called

- 81 mysterin, causes urticarial lesions associated with a clinically-blunted hypercytokinemia.
- 82

83 KEY WORDS

- 84 RNF213, hypercytokinemia, urticarial lesions, genetics
- 85

86 ABBREVIATIONS

- 87 CYLD: cylindromatosis
- 88 COVID-19: coronavirus-19 disease
- 89 CRP: C-reactive protein
- 90 DEG: differentially expressed genes
- 91 gnomAD: genome-aggregation database
- 92 HLA: human-leukocyte-antigen
- 93 IL: interleukin
- 94 IL-1RA: IL-1 receptor antagonist
- 95 IFN- γ : interferon- γ
- 96 LOD: logarithm of the odds
- 97 LPS: lipopolysaccharide
- 98 MHC II: major histocompatibility complex class II
- 99 MMD: moyamoya disease
- 100 RING: really interesting new gene
- 101 RNF213: ring-finger protein-213
- 102 SAIDs: systemic autoinflammatory diseases
- 103 SAA: serum amyloid A
- 104 TNF- α : tumor necrosis factor- α
- 105 WT: wild type

106 MAIN TEXT

107

108 Introduction

109

Urticaria is a common clinical condition characterized by the development of wheals and/or angioedema^{1, 2}. Typical features of wheals include an itching sensation and a fleeting nature, the wheals lasting no more than 24 to 36 hours with no residual skin changes, whereas in its chronic form, the episodes last more than six weeks¹. In addition, the patients with urticaria usually do not present with systemic symptoms.

In contrast to urticaria, the so-called "urticaria-like skin lesions" (or "urticarial skin 115 lesions") are typically non-pruritic. They have a long duration, wheals are fixed, lasting several 116 days or weeks and their resolution frequently leaves marks such as hyperpigmentation. In 117 118 addition, systemic symptoms can coexist thereby defining systemic urticarial syndromes as is the case with disorders like urticarial vasculitis or like systemic autoinflammatory disorders 119 120 (SAIDs), a group of rare heterogeneous diseases partly explained by mutations in genes that regulate the innate immune response³. In SAIDs, the recurrent episodes of systemic 121 inflammation are driven by an excessive production of pro-inflammatory cytokines. 122

Herein, we report a genetic disease characterized by that, from a nosographic point of view, 123 does not fall into any of the above-mentioned groups of diseases. Chronic urticarial lesions 124 evolving by flares are the only clinical symptoms that segregate as a fully penetrant autosomal-125 dominant trait within a large family in which several affected members present persistent and 126 massive -but extremely well-tolerated-hypercytokinemia. Genetic linkage analysis combined 127 with whole-exome sequencing identified a disease-causing germline mutation in ring-finger 128 protein-213 (RNF213), which encodes a protein called mysterin whose biological properties are 129 still largely unknown. Unsupervised transcriptomic and proteomic approaches enabled 130 exploration of RNF213-dependent biological pathways implicated in this new entity. 131

- 133 Methods
- 134

135 Patients

Clinical features were collected through a standardized form. The study conforms to the Helsinki declaration regarding ethical principles for medical research. Written informed consents were obtained from each patient or their parents.

139

140 Genetic studies

141 Genomic DNA samples were obtained from 16 family members.

Whole-genome genotyping of 14 family members (affected and healthy) used the Infinium Human Linkage-12 Genotyping BeadChip (Illumina). The BeadChip includes 6090 common single-nucleotide polymorphism markers with an average spacing of 441 kb and 0.58 centimorgan (cM) across the genome. Linkage analysis was performed with Merlin 1.1.2 software, assuming autosomal-dominant inheritance, full penetrance, no consanguinity and a mutation-allele frequency < 0.001.

Genomic DNA samples prepared from peripheral blood leukocytes of patients 1 (P1) and 2 (P2) were subjected to whole-exome sequencing, using the FlexiGene Kit (Qiagen). Exomesequence libraries were prepared using a SeqCap EZ Human Exome Library Kit version 3.0 (Roche NimbleGen) and sequenced using a Nextseq500 (Illumina). The identified sequence variation was validated by Sanger sequencing on an ABI 3130 XL automated capillary DNA sequencer (Applied Biosystems).

154

155 Histological analysis

A skin punch biopsy was obtained from patient P1 under local anesthesia, then formalin-fixed 156 and paraffin-embedded. Tissue sections (3-µm thick) were stained with hematoxylin, eosin and 157 saffron and, after antigen retrieval by heat in appropriate buffer, immunolabeled with anti-CD3 158 (F.7.2.38 mouse monoclonal antibody, Dako), CD4 (4B12 monoclonal antibody, Leica), CD8 159 (C8/144B mouse monoclonal antibody, Dako), perforin (5B10 mouse monoclonal antibody, 160 BioSB, Diagomics), granzyme B (11F1 mouse monoclonal antibody, Leica) and FOXP3 161 (236A/E7 mouse monoclonal antibody, Abcam) antibodies, using the Bond III device (Leica 162 Microsystems). 163

164

165 **RNF213 plasmid constructs and transfection**

After reverse transcription, full-length *RNF213* cDNA underwent polymerase-chain reaction amplification (RT-PCR; Transcriptor High Fidelity cDNA Synthesis Kit, Roche) in two fragments of the *RNF213* transcripts. Each fragment was subcloned into pcDNA3.1/V5-His TOPO TA (Invitrogen). Each of the full-length *RNF213* cDNAs (WT and C41777R) was subsequently assembled into the pmaxGFP expression vector using the NEB builder Hifi DNA-Assembly Kit (New England BioLabs). Detailed method is provided in the **Suplemental data**

172 **1 in the Online Repository.**

HEK293T cells were transfected with different amounts of *RNF213* plasmids using
FUGENE HD (Promega).

175

176 *Cell-culture conditions*

Monocytes were isolated from peripheral blood (EDTA-containing tubes) of P1, P2 and healthy donors provided by the Etablissement Français du Sang. For cytokine measurements, adherent monocytes were treated for 24 hours with 100 ng/ml lipopolysaccharide (LPS) and cell-culture supernatants were used for ELISA.

- 181 Dermal fibroblasts were isolated from skin biopsies obtained from P1, P2 and two healthy 182 donors after obtaining their informed consent according to the Declaration of Helsinki.
- 183 Immortalized B lymphocytes were generated from three healthy donors' peripheral blood,
- 184 at the Centre de Ressources Biologiques of Cochin Hospital (APHP, Paris).
- 185 HEK293T cells were maintained in standard conditions.
- 186 Detailed methods are provided in the **Supplemental data 1 in the Online Repository.**
- 187

188 Cytokine measurements

Patients' – P1, P2, P3 and P4 – and controls' plasma samples were prepared and stored immediately at -80° C, until analysis. Supernatants of adherent monocytes isolated from healthy controls' and patients' blood samples were centrifuged for 10 minutes at 250 g and stored at -80° C, until analysis. Cytokine concentrations were determined with ELISAs, according to the manufacturer's instructions (DuoSet ELISA kits, R&D, Biotechne).

194

195 Cell-lysate preparations

Cells (fibroblasts, immortalized B lymphocytes and HEK293T cells) were suspended in icecold lysis buffer (50 mM Tris, 100 mM NaCl, 5 mM EDTA, 1% Triton X–100, and phosphatase inhibitor (Roche Diagnostics) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics). Lysates were incubated for 1 hour under agitation at 4°C and cleared by 10 200

minutes of centrifugation at 1000 g, 4° C.

201

202 Antibodies

Rabbit anti-human RNF213 polyclonal antibody (HPA003347, Sigma) was used for
immunoprecipitation and immunoblot assays. Mouse anti-human cylindromatosis (CYLD)
monoclonal antibody (sc-74434, Santa Cruz Biotechnology) and rabbit anti-human CYLD
(D1A10) polyclonal antibody (8462S, Cell Signaling) were used for immunoblotting.

207

208 Immunoblotting

Cell lysates were loaded onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis 209 (SDS-PAGE) plates, transferred onto a PolyVinyliDene Fluoride (PVDF) or nitrocellulose 210 membranes, blocked for 1 hour in PBS-Tween 0.1% (PBS-T)-5% skim milk and analyzed by 211 212 Western-blotting with different antibodies, incubated overnight at 4°C in PBS-T–5% milk. The secondary antibody (rabbit- or mouse-horseradish peroxidase) was incubated for 1 hour at 213 room temperature in PBS-T-5% milk. Proteins were detected with Amersham ECL Select 214 Western-Blotting Detection Reagent (GE healthcare), according to the manufacturer's 215 recommendations. 216

217

218 Cycloheximide (CHX) assay

HEK293T cells were transfected with RNF213_WT or RNF213_C4177R and treated with CHX (100 μ g/ml) at different times during the 24 hours posttransfection, then washed with PBS and stored at -20°C until analysis.

222

223 Immunoprecipitation

Cell lysates (500 μ l) of immortalized B cells and HEK293T cells were incubated overnight at 4°C with 2 μ g of the anti-human RNF213 antibody. Cell lysates/antibody mixtures were then incubated with PierceTM Protein G Magnetic Beads (ThermoFisher) for 1 hour at 4°C and washed five times with 500 μ l of ice-cold lysis buffer, before being eluted after a 15-minute incubation with 40 μ l of Leammli buffer.

229

230 Nanoscale liquid chromatography coupled to tandem mass spectrometry (NanoLC MS/MS)

231 protein identification and quantification

232 Immunoprecipitation (IP) eluates were subjected to S-TrapTM micro-spin column digestion.

233 Samples were injected into a nanoRSLC-Q Exactive PLUS (RSLC Ultimate 3000) (Thermo

- Scientific). Peptides were loaded onto a μ-precolumn, and separated on a 50-cm reversed-phase
 liquid-chromatography column (Thermo Scientific). Peptides eluted from the column were
 analyzed by data-dependent MS/MS, using the top-10 acquisition method. Detailed method is
- 237 provided in the **Supplemental data 1 in the Online Repository**.
- 238

239 NF-KB luciferase-reporter assay

HEK293T cells were co-transfected in 12-well plates with the following plasmids: 100 ng of *Firefly* luciferase-expression plasmid driven by NF-κB-responsive elements (pGL4.32,
Promega), and 50 and 200 ng of pmaxGFP-vector or pRNF213-expression plasmids. Cells were
lysed 40 hours posttransfection and subjected to luciferase-reporter assays (Promega) using a
TriStar LB 941 Multimode Microplate Reader (Berthold Technologies).

245

246 Quantitative RT-PCR

Total RNA (1µg) from dermal fibroblasts was extracted using the RNeasy Mini Kit (Qiagen) and then subjected to reverse transcription with the Reverse Transcriptor Kit (Roche). The realtime PCR assays were performed in the Light Cycler LC480 (Roche). Detailed method is provided in the Supplemental data 1 in the Online Repository.

251

252 **RNA-sequencing and transcriptomics analyses**

mRNA-sequencing libraries (mRNA isolated from the monocytes of P1 and P2 and two healthy controls) were prepared with TruSeq Stranded mRNA kit (Illumina), according to supplier's recommendations and sequenced on paired-end 75 bp of Illumina HiSeq4000. Detailed method is provided in the **Supplemental data 1 in the Online Repository.**

RNA-Seq data are deposited at the National Center for Biotechnology Information in the Gene
Expression Omnibus database (<u>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168721</u>,
token: upahmkssptmfhcb).

260

261 Analysis of proteomics data

Results of RNF213 IP followed by nanoLC-MS/MS protein identification were analyzed with Perseus software. To avoid false-positive partners, only high-confidence interactions and specific interactions (interactors not detected with beads alone without IP) were retained.

Metascape (<u>http://metascape.org</u>)⁴ was used on gene lists to analyze enrichment. That analysis included terms from Reactome Gene Sets, GO Biological Processes, and KEGG Pathways.

268

269 Statistical analyses

- 270 Differences were analyzed using unpaired Student *t*-tests and were plotted with Prism 9,
- 271 GraphPad software, (San Diego, CA). A *P* value ≤ 0.05 defined statistical significance.

- 273 **Results**
- 274

275 Disease phenotype

We studied a multiplex family with urticarial lesions segregating as an autosomal-dominant 276 trait (Figure 1A). Affected family members had early-onset episodes (age 6 months to 25 years) 277 of nonpruritic fixed urticarial lesions characterized by erythematous and edematous hives 278 spontaneously resolving after several weeks into large violaceous macules that fade over time, 279 but persist over months or years (Figure 1B). These cutaneous lesions displayed an episodic 280 course and were triggered by seasonal temperature variations; the patients spontaneously 281 reported an exacerbation of their cutaneous symptoms after a drop in ambient temperature. 282 283 However, all the ice cube tests performed in one of the patients (Patient 1) remained negative.

Patient 1 (P1), now a 55-year-old woman, first consulted in our dermatology department in 284 1987, because of the occurrence since the age of 12 of erythematous, nonpruritic, urticarial 285 lesions on her ankles. Over the years, as the flares became more frequent, cutaneous lesions 286 287 extended over the trunk, arms, legs and face. During her 35-year follow-up, she never experienced any other symptoms: especially no fever, arthralgias or angioedema. Histological 288 examination of P1's biopsied lesional skin revealed minor inflammatory infiltrates in the upper 289 dermis, interspersed with uninvolved, normal epidermis. Infiltrates were comprised of small 290 lymphocytes admixed with few neutrophils and scattered nuclear debris, without vasculitis 291 (Figure E1 in the Online Repository). The investigations performed over the years 292 documented chronic lymphopenia (0.4 to 0.6 G/l), with markedly low CD4+ T cells (167 293 cells/µl) and modestly low CD8+ T cells (167 cells/µl) (see Figure E2.A in the Online 294 **Repository**) and, sometimes, antinuclear antibody-positivity (titers range 80 to 1280, with no 295 other autoantibodies). Conventional inflammatory parameters, e.g., Plasma C-reactive protein 296 (CRP) and serum amyloid A (SAA) levels were within normal and in subnormal ranges, 297 respectively. Complement system tests (total complement activity, C3 and C4) were also within 298 normal ranges (see Figure E2.A in the Online Repository). Serum-protein electrophoresis 299 300 showed mild polyclonal gammopathy with no monoclonal gammopathy. Although no definite diagnosis could be made, and because of the psycho-social burden experienced by P1, several 301 302 treatment lines, e.g., antihistamines, hydroxychloroquine, methotrexate, thalidomide, dapsone or colchicine, were tried but had no efficacy. More targeted treatment such as anakinra or 303 adalimumab were prescribed, each for 3 to 6 months with no regression of the cutaneous 304 lesions. Prednisone 20 mg/day or topical clobetasol propionate 0.05% (20 g/day) provided 305 306 partial lesion attenuation but was difficult to sustain over the long-term.

Patient 2 (P2) is a 56-year-old woman who first consulted in our department in 1987 because of skin lesions, similar to those of her sister P1, and localized on arms and buttocks. The lesions appeared when she was 1-year old but did not extend over the years. During her 34-year followup, she did not complain of any other symptoms. Like her sister, no biological inflammation was observed (see Figure E2.A in the Online Repository). Topical clobetasol propionate

- 312 0.05% (20 g/week) provided partial lesion attenuation.
- Other affected family members: Nine other family members exhibiting the same cutaneous lesions were identified (Figure 1C). All of them had early-onset episodes (from the age of 6 months to 25 years). The lesions were similar to those of P1 and P2. None of the patients reported other symptoms, fever, arthralgias or angioedema. Furthermore, they never had serious infections. Routine biological tests performed in 4 of these patients are provided in Figure E2.A
- 318 in the Online Repository.

Notably, a large intrafamilial contamination with COVID-19 (confirmed by SARS-Cov-2 Realtime PCR test assay) occurred in 2020. None of the family members was vaccinated at that time. P1 had transitory anosmia, headaches and odynophagia, and her 87-year-old mother, transient fever and fatigue. The other affected family members were asymptomatic.

323

324 Massive hypercytokinemia and monocyte immunosuppression

P1's and P2's plasma inflammatory cytokine levels were determined at different times over 325 3 years. Plasma levels of proinflammatory (e.g., interleukin (IL)-1β, IL-6, IL-1α, IL-8 and 326 tumor necrosis factor- α (TNF- α)) and anti-inflammatory mediators (like IL-1 receptor-327 antagonist (IL1-RA) and IL-10) were extremely elevated, P1 having higher plasma levels of all 328 329 cytokines (Figure 2A). Moreover, P1 had high levels of the Th2-type cytokine IL-4, while P2's IL-4 was below the detection limit. Conversely, P1's and P2's Th1-type cytokines IL-12 and 330 interferon- γ (IFN- γ) were comparable to those of healthy controls (**Figure 2A**). Levels of all 331 these cytokines remained constant over time, even when P1 received anti-TNF (adalimumab) 332 or anti-IL1 (anakinra) agents. We also measured, in the same assay; the plasma cytokine levels 333 (i.e., IL-1 β , TNF- α , IL-6 and IL-10) of P1 and P2 together with two additional patients from 334 this family (P3 and P4) (see Figure E2.B in the Online Repository). This analysis revealed 335 that the hypercytokinemia of P1 and P4-the patients with the most severe skin lesions-was 336 337 massive, whereas, P3, had cytokine levels within the normal range. Furthermore, we studied cytokine secretion in the supernatants of monocytes isolated from 338

339 P1, P2 and healthy donors, before and after lipopolysaccharide (LPS) stimulation. Notably,

after LPS stimulation, P1's and P2's IL-1 β levels were significantly lower in their monocyte supernatants than in those of healthy controls, while the other cytokines tested (TNF- α , IL-6 and IL-18) did not differ significantly (**Figure 2B**). Additionally, the amount of IL-6 in the supernatants of cultured skin fibroblasts isolated from P1 and P2 was similar to that of healthy

donors (see Figure E2.C in the Online Repository).

In an attempt to identify a possible dysregulation of the gene networks associated with this 345 massive hypercytokinemia, monocytes from P1, P2 and two healthy controls were subjected to 346 transcriptomic analysis (RNA-Seq). Differentially expressed genes (DEGs) were analyzed 347 between each patient and mean healthy control values (i.e., DEGs with $P \le 0.05$ and a |fold 348 change ≥ 1.5). That analysis showed that P1's gene-expression dysregulation was more 349 pronounced than P2's (2,011 and 675 DEGs, respectively, see Table E1.A and E1.B in the 350 **Online Repository**), in keeping with the severity of their disease phenotypes. The significantly 351 upregulated gene set was enriched in several pathways, such as: "positive regulation of cell 352 migration" (GO:0030335), "myeloid leukocyte activation" (GO:0002274) and "response to 353 bacterium" (GO:0003617) (Figure 2C, see Figure E3.A, Table E1.C and E1.D in the Online 354 **Repository**), and mainly concerned P1 who has a more severe disease. Notably, eight of P1's 355 top-20 upregulated genes (OLFM4, RETN, BPI, LCN2, LTF, CAMP, MMP8 and ARG1) are 356 overexpressed during sepsis⁵⁻⁹ (see Figure E3.B in the Online Repository), with ARG1 being 357 considered a potential mediator of sepsis-induced immunosuppression⁸. 358

To further investigate the relationships between P1's transcriptomic profile and that of 359 patients with sepsis (i.e., patients with prominent hypercytokinemia), we took advantage of 360 available transcriptomic datasets (GSE133822) from the monocytes of 33 patients with sepsis⁸. 361 362 While relying on the list of P1's DEGs, we computed Pearson's correlation coefficients (using fold-change values) between P1, P2 or each of the 33 septic patients versus healthy samples 363 from the same dataset, and between each of the 33 septic patients (Figure 2D). A strong 364 correlation was found between P1's transcriptomic data and that of each septic patient, similar 365 to what was found between each of the 33 septic patients (respective mean coefficient 366 correlations of 0.36 and 0.42, see Table E1.E in the Online Repository). Among the set of 367 downregulated genes (see Figure E3.C, Table E1.F and E1.G in the Online Repository), P1's 368 human-leukocyte-antigen (HLA) transcripts encoding the cell-surface receptors of major 369 histocompatibility complex class II (MHC II), including HLA-DR, were downregulated 370 (Figure 2E); such HLA-DR downregulation is a known biomarker of monocyte 371 immunosuppression¹⁰. 372

374 Identification of a pathogenic mutation in RNF213

To determine the molecular basis of this condition that segregates as an autosomal-dominant 375 trait (Figure 1A) with complete penetrance and variable expressivity, genetic linkage analysis 376 was done on 14 family members. A significant logarithm of the odds (LOD) score was 377 identified for a single 3.3-Mb region of chromosome 17 (chr17:76141133-79461642; hg19 378 genome assembly) (see Figure E4.A in the Online Repository). Whole-exome sequencing of 379 P1 and P2 identified a single variation absent from the genome-aggregation database 380 (gnomAD): c.12529T>C p.(Cys4177Arg) in RNF213, a large gene that contains 68 exons (see 381 Figures E4.B to E4.D in the Online Repository and Figure 3A). As expected from the genetic 382 linkage data, this missense variation perfectly segregates with the phenotypic status of all 16 383 family members tested (Figure 1A). The RNF213 protein (also known as mysterin) is a large, 384 ubiquitously expressed 5207-amino-acid protein. It comprises an AAA core with ATPase 385 activity and an E3 module harboring a RING (really interesting new gene)-finger domain with 386 E3 ubiquitin-ligase activity¹¹. The identified sequence variation leads to amino-acid substitution 387 388 at codon 4177 involving a cysteine, invariant throughout evolution and located within the E3 module (Figure 3A). Taken together, these data strongly suggest that the c.12529T>C 389 p.(Cys4177Arg) missense variation identified in *RNF213* is causative in this family. 390

To further confirm this hypothesis, we first assessed the potential impact of the identified missense variation on RNF213 transcripts and proteins isolated from the patients' dermal fibroblasts (two independent skin biopsies (P1- and P2SB1, and P1- and P2SB2) for each patient). *RNF213*-mRNA expression did not differ between patients' fibroblasts and those of controls (see **Figure E5.A in the Online Repository**). However, RNF213-protein levels were significantly lower in both patients' fibroblasts, suggesting that the p.(Cys4177Arg) variation affected RNF213 half-life (**Figure 3B** and **see Figure E5.B in the Online Repository**).

After subcloning the full-length 15-kb *RNF213* cDNA in a eukaryotic expression vector, RNF213 stability was examined in HEK293T cells expressing recombinant forms of the protein carrying the p.(Cys4177Arg) variation or not (i.e., RNF213_C4177R or wild-type RNF213_WT, respectively). The experimental results revealed a shorter half-life RNF213_C4177R as compared to its WT counterpart (4 vs. 6.5 hours, P = 0.0234; **Figure 3C**, see **Figure E5.C in the Online Repository**), a result supporting that the p.(Cys4177Arg) variation is a loss-of-function mutation.

Taking advantage of the recent finding suggesting that RNF213 is a positive regulator of NF- κ B signaling^{12, 13}, we used an NF- κ B-dependent luciferase-reporter assay to assess the impact of the identified mutation on that signaling activity (**Figure 3D**). As expected,

408 HEK293T cells transfected with the expression plasmid encoding RNF213_WT displayed 409 enhanced NF- κ B activity, compared to mock-transfected cells; however, cells expressing 410 RNF213_C4177R had completely lost NF- κ B activation.

Taken together, these observations demonstrate RNF213 involvement in the pathogenesis of
family's disease phenotype.

413

414 **RNF213** role in inflammation

415 To further investigate the molecular mechanism underlying this disease condition and gain additional insight into the RNF213-dependent biological pathways, we used an unsupervised 416 proteomic approach to identify cell-protein partners interacting with RNF213. To do so, we 417 immunoprecipitated RNF213 from two different cell types—immortalized B cells (from three 418 healthy controls) and native HEK293T cells-followed by nanoLC-MS/MS protein 419 identification and quantification. That analysis identified 104 RNF213 interactors, 64 in 420 immortalized B cells and 60 in HEK293T cells, with 20 shared by B cells and HEK293T cells 421 (see Figure E6.A, Table E2.A and E2.B in the Online Repository), thereby confirming the 422 robustness of the approach used. 423

Protein-enrichment analysis revealed RNF213-associated biological pathways, several of 424 which agree well with the patients' hypercytokinemia, i.e., "cytokine-mediated signaling 425 pathways" (GO:0019221), and with innate immunity, i.e., "budding and maturation of HIV 426 virions" (R-HSA-162588), and "positive regulation of viral release from host cells" 427 428 (GO:1902188) (Figure 4A, and see Table E2.C and E2.D in the Online Repository). Notably, the proteins involved in the cytokine-mediated signaling pathway include well-known 429 430 immunity regulators, such as CYLD, ISG15, OAS2 and ISG20. Among them, CYLD (cylindromatosis), detected in both cell types, is a deubiquitinase that negatively regulates the 431 NF-κB pathway¹⁴. The RNF213–CYLD interaction was confirmed in HEK293T by co-432 immunoprecipitation followed by western-blot analysis (see Figure E5.B in the Online 433 **Repository**). 434

We subsequently tested the impact of RNF213 on CYLD expression, to determine whether the latter could represent a functional link between RNF213 and the NF- κ B pathway. To this end, HEK293T cells were transfected with the RNF213_WT- or RNF213_C4177R-encoding constructs (**Figure 4C**). RNF213_WT-expressing cells expressed significantly less CYLD protein than mock-transfected cells, and that lower expression was partially lost when cells were transfected with mutated *RNF213* (**Figure 4C**). These CYLD-expression results are consistent with the effects of RNF213_WT and RNF213_C4177R that we observed on NF-κB
activation (Figure 3D).

443

444 Discussion

445

Herein, we describe a novel entity characterized by the association of urticarial lesions with chronic and massive —but well-tolerated—hypercytokinemia. We provide genetic and molecular evidence supporting that this disease, which is a genetic condition segregating as a fully penetrant trait with variable expressivity, is due to a germline mutation in *RNF213*. Additional functional studies based on unsupervised approaches identified the key role played by mysterin—the *RNF213*-encoded protein—in the complex network of proteins involved in innate immunity.

From a nosographic viewpoint, it is important to underline the fact that the skin lesions of this family, although ressembling urticaria, differ from urticaria in that they are non-pruritic and fixed, spontaneously resolving in pigmented scares that fade over time. Moreover, unlike what is observed in SAIDs, the patients from this family have never reported any inflammatory systemic symptom (while P1 and P2 have been followed twice a year for more than 30 years). Furthermore, in spite of the absence of systemic symptoms, several patients have extremely high plasma cytokine levels.

The hypercytokinemia identified in P1 and P2 from this family is not an acute phenomenon 460 but persists in a chronic state, as documented by the patients' long-term follow-up. In P1, the 461 most severely affected, several proinflammatory cytokine levels (e.g., IL-1 β , TNF- α or IL-6) 462 were much higher than those found in patients with an acute cytokine storm requiring intensive 463 care, as seen in patients with severe sepsis¹⁵ or COVID-19^{16, 17}. Paradoxically, in our patients, 464 the disease is extremely well-tolerated, without any organ dysfunction or general symptoms. 465 The patients remained apyretic and plasma levels of common biological markers of systemic 466 inflammation (e.g., CRP) were within normal ranges. 467

In an attempt to at least partly explain this clinical–biological dissociation, additional biological assays were undertaken. Indeed, the proinflammatory phenotype was associated with high plasma levels of IL-1–receptor antagonist and IL-10, two markers of an anti-inflammatory response. Transcriptomic analyses revealed an immunosuppressive phenotype of P1's monocytes, including less expression of MHC class II transcripts, thereby mimicking sepsisinduced immunosuppression. Pertinently, severe COVID-19 patients also exhibit these features^{14, 15}.

P1's chronic lymphopenia is another element shared with septic patients in whom 475 lymphopenia is a well-known phenomenon attributed to apoptosis¹⁸. In this context, it is worth 476 noting that apoptosis contributes to sepsis-induced immunosuppression¹⁰ through the immune 477 tolerance induced by IL-10 secretion⁶ and the shift of the Th1/Th2 balance towards Th2 cells¹⁹. 478 P1's cytokine profile clearly favors this Th2 profile, with high plasma IL-4 and IL-10 479 concentrations associated with IFN- γ and IL-12 levels below the limit of detection. In contrast 480 to patients with sepsis-induced cytokine storms, our patients had no heightened susceptibility 481 to infections known to occur in acquired immunosuppression. As just recently noted, the 482 483 putative impact of inborn errors in RNF213 on adaptative immune responses is so far unknown²⁰. The fact that our patients have no heightened susceptibility to infections provides 484 a first answer to that question. 485

This disease, which is caused by a germline pathogenic RNF213 mutation, is so far revealed 486 by the study of a single family. Identification of additional families with inborn errors of 487 RNF213 associated with immune dysregulation would be of great help to better characterize 488 this new disease entity. It should, however, be noted that the current data rely on the study of a 489 490 five-generation family with more than 10 affected patients, the in-depth phenotyping of two of these patients through ~35 years of longitudinal follow-up, and a genetic strategy based on two 491 492 unsupervised approaches (i.e., whole-genome linkage analysis with a LOD score >3 and whole 493 exome sequencing). In addition, the results of different functional tests (i.e., CHX and NF-κB luciferase-reporter assays) confirmed that the sequence variation identified in RNF213 is 494 495 disease-causing. Notably, other RNF213 sequence variations have been associated with moyamoya disease (MMD), a rare cerebral angiopathy characterized by progressive stenosis of 496 the intracranial and internal carotid arteries, engendering ischemic and hemorrhagic stroke^{21, 22}. 497 In MMD, some RNF213 variants, which are low-penetrant variants, are commonly considered 498 499 genetic-susceptibility factors, suggesting that additional factors are required to develop the disease. In this setting, the identification of over 100 new RNF213-protein partners is valuable 500 501 information that could contribute greatly to further deciphering MMD pathophysiology. Recently, two patients with a severe syndromic form of moyamoya disease (MMD) including 502 skin involvement and de novo RNF213 missense variations have been reported in a clinical 503 report²³. Notably, for one of the two patients, the description of the skin lesions recalls the 504 urticarial lesions observed in our family. Although no studies were performed to assess the 505 functional consequences of the identified RNF213 missense variations, the possibility that the 506 disease of our family and of these two sporadic cases belong to the same nosological entity 507 508 remains open.

In our study, RNF213 emerges as a new innate-immunity actor playing a key role in 509 inflammation. That finding agrees with very recent results emphasizing RNF213's role during 510 bacterial and viral infection^{20, 24, 25}. Our analyses identified CYLD, an RNF213 cell-protein 511 partner, as a potential missing link accounting for the ability of RNF213 to activate the NF-KB 512 pathway. As demonstrated herein, RNF213 inhibited CYLD expression and, accordingly, the 513 mutated RNF213 carrying the p.(Cys4177Arg) loss-of-function mutation failed to inhibit 514 CYLD expression. Most importantly, CYLD deubiquitinase, which is known to inhibit the NF-515 κ B pathway, activates cell death¹⁴. And as shown in the mouse, such cell death, in turn, drives 516 severe skin inflammation²⁶. It is therefore tempting to speculate that the impaired CYLD 517 suppression observed in the context of RNF213_C4177R is at least in part responsible for our 518 519 patients' skin condition. Notably, a similar NF-kB blockade has already been described in genetic diseases with skin inflammation such as those due to loss-of-function mutations in 520 *IKBKG* (the gene encoding NEMO, a substrate of CYLD)²⁷, in *RELA* (the gene encoding p65, 521 a NF- κ B subunit)²⁸ or in *CARD14*²⁹. 522

In summary, we describe a disease entity, characterized by urticarial lesions that segregate as a fully penetrant autosomal-dominant trait associated with a chronic, massive and clinically blunted hypercytokinemia. The genetic and functional data obtained during the course of this study, which reveal the critical role RNF213 played in innate immunity, should open new avenues for identifying novel insights in the regulation of the immune system. Identification of additional families with inborn errors of *RNF213* associated with immune dysregulation should help to better characterize this new disease entity and, therefore, identify an effective therapy.

531 ACKNOWLEDGMENTS

- 532 We are grateful to the patients and their family, whose cooperation made this study possible
- and Prof. Laurence Fardet for her contribution to clinical data acquisition. We also would like
- to thank Janet Jacobson for editing the manuscript.
- 535

536 **REFERENCES**

- 537
- 5381.Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al.539The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification,540diagnosis and management of urticaria. Allergy 2018; 73:1393-414.
- Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what
 else? The differential diagnosis of urticaria: part I. Cutaneous diseases J Am Acad
 Dermatol 2010; 62:541-55.
- 5443.Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory545diseases define new pathways in human innate immunity and inflammation. Nat546Immunol 2017; 18:832-42.
- 547 4. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al.
 548 Metascape provides a biologist-oriented resource for the analysis of systems-level 549 datasets. Nat Commun 2019; 10:1523.
- 5. Almansa R, Ortega A, Avila-Alonso A, Heredia-Rodriguez M, Martin S, Benavides D,
 et al. Quantification of Immune Dysregulation by Next-generation Polymerase Chain
 Reaction to Improve Sepsis Diagnosis in Surgical Patients. Ann Surg 2019; 269:54553.
- 5546.Cohen G, Ilic D, Raupachova J, Horl WH. Resistin inhibits essential functions of555polymorphonuclear leukocytes. J Immunol 2008; 181:3761-8.
- 556 7. Martin L, van Meegern A, Doemming S, Schuerholz T. Antimicrobial Peptides in
 557 Human Sepsis. Front Immunol 2015; 6:404.
- Washburn ML, Wang Z, Walton AH, Goedegebuure SP, Figueroa DJ, Van Horn S, et
 al. T Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic
 Critically Ill Patients and in Patients with Cancer. J Immunol 2019; 203:1897-908.
- Hu Z, Murakami T, Suzuki K, Tamura H, Reich J, Kuwahara-Arai K, et al.
 Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice. Int Immunol 2016; 28:245-53.
- Venet F, Demaret J, Gossez M, Monneret G. Myeloid cells in sepsis-acquired
 immunodeficiency. Ann N Y Acad Sci 2020.
- Ahel J, Lehner A, Vogel A, Schleiffer A, Meinhart A, Haselbach D, et al. Moyamoya
 disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct
 ubiquitin-transfer mechanism. Elife 2020; 9.
- Piccolis M, Bond LM, Kampmann M, Pulimeno P, Chitraju C, Jayson CBK, et al.
 Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids.
 Mol Cell 2019; 74:32-44 e8.

- Takeda M, Tezuka T, Kim M, Choi J, Oichi Y, Kobayashi H, et al. Moyamoya disease
 patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity
 and enhance NFkappaB activation and apoptosis in an AAA+ domain-dependent
 manner. Biochem Biophys Res Commun 2020; 525:668-74.
- Lork M, Verhelst K, Beyaert R. CYLD, A20 and OTULIN deubiquitinases in NFkappaB signaling and cell death: so similar, yet so different. Cell Death Differ 2017;
 24:1172-83.
- 579 15. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine
 580 profile in patients with severe sepsis: a marker for prognosis and future therapeutic
 581 options. J Infect Dis 2000; 181:176-80.
- Wang SY, Takahashi T, Pine AB, Damsky WE, Simonov M, Zhang Y, et al. Challenges
 in interpreting cytokine data in COVID-19 affect patient care and management. PLoS
 Biol 2021; 19:e3001373.
- 585 17. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
 586 Antonakos N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe
 587 Respiratory Failure. Cell Host Microbe 2020; 27:992-1000 e3.
- Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular
 dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13:862-74.
- 590 19. Girkontaite I, Urbonaviciute V, Maseda D, Neubert K, Herrmann M, Voll RE.
 591 Apoptotic cells selectively suppress the Th1 cytokine interferon gamma in stimulated
 592 human peripheral blood mononuclear cells and shift the Th1/Th2 balance towards Th2.
 593 Autoimmunity 2007; 40:327-30.
- Thery F, Martina L, Asselman C, Zhang Y, Vessely M, Repo H, et al. Ring finger
 protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity.
 Nat Commun 2021; 12:5772.
- 597 21. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome598 wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum
 599 Genet 2011; 56:34-40.
- Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al.
 Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible
 role in vascular development. PLoS One 2011; 6:e22542.
- Strong A, O'Grady G, Shih E, Bishop JR, Loomes K, Diamond T, et al. A new syndrome of moyamoya disease, kidney dysplasia, aminotransferase elevation, and skin disease associated with de novo variants in RNF213. American Journal of Medical Genetics Part A 2021; 185:2168-74.
- 607 24. Otten EG, Werner E, Crespillo-Casado A, Boyle KB, Dharamdasani V, Pathe C, et al.
 608 Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature
 609 2021.
- Houzelstein D, Simon-Chazottes D, Batista L, Tokuda S, Langa Vives F, Flamand M,
 et al. The ring finger protein 213 gene (Rnf213) contributes to Rift Valley fever
 resistance in mice. Mamm Genome 2021; 32:30-7.
- 613 26. Kumari S, Van TM, Preukschat D, Schuenke H, Basic M, Bleich A, et al. NF-kappa B
 614 inhibition in keratinocytes causes RIPK1-mediated necroptosis and skin inflammation.
 615 Life Science Alliance 2021; 4.

- Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, et al. Genomic
 rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia
 pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000;
 405:466-72.
- Badran YR, Dedeoglu F, Castillo JML, Bainter W, Ohsumi TK, Bousvaros A, et al.
 Human RELA haploinsufficiency results in autosomal-dominant chronic
 mucocutaneous ulceration. Journal of Experimental Medicine 2017; 214:1937-47.
- Peled A, Sarig O, Sun GP, Samuelov L, Ma CA, Zhang Y, et al. Loss-of-function
 mutations in caspase recruitment domain-containing protein 14 (CARD14) are
 associated with a severe variant of atopic dermatitis. Journal of Allergy and Clinical
 Immunology 2019; 143:173-+.

627

628

630 CONFLICT OF INTEREST

632 The authors have no conflict of interest to declare.

635 FIGURE LEGENDS

636

Figure 1. Genealogical tree of the studied family and clinical manifestations in affected

638 **members.** (A) Genealogical family tree showing co-segregation of chronic urticarial lesions

(filled symbols) with the identified *RNF213* pathogenic variation. †, died (**B**) Patient 1's (P1)

and 2's (P2) urticarial lesions. N: normal allele, M: mutated allele. (C) Clinical characteristics

- 641 of affected family members.
- 642

643 Figure 2. Hypercytokinemia and monocyte immunosuppression. (A) ELISA-assessed

644 plasma-cytokine levels of patients P1 and P2 (over 3 years) and 9–10 healthy donors (Ctr).

(B) Cytokines (ELISA) in the supernatants of P1's (n = 4) and P2's (n = 4) and 5–6 healthy

- 646 controls' untreated or lipopolysaccharide (LPS)-stimulated monocytes. A & B: means \pm
- 647 standard deviation. (C–E) RNA-Seq analyses of patients' monocytes expressed as fold
- 648 changes (FC) compared to the mean Ctr value. (C) Heatmap of enriched terms across the list

of patients' up-regulated genes, colored by *P*-values. (**D**) Heatmap of Pearson's correlation

650 coefficients using patients' RNA-Seq data and 33 septic patients' monocyte transcriptomic

datasets (GSE133822)⁵. Based on P1's list differently expressed genes (DEGs, |FC| > 1.5, P < 1.5, P <

652 0.05), Pearson's correlation coefficients (FC values) were calculated between P1 or P2 and

each of the 33 septic patients and between each of the 33 septic patients (mean correlation

- coefficients = 0.36, 0.05 and 0.42, respectively). (E) |FCs| of P1's and P2's HLA mRNAs
- encoding major histocompatibility complex class II (MHCII). Underlined DEG values are

significant (> 1.5, P < 0.05). Two-tailed P values were determined with unpaired *t*-tests. ns: not significant; $*P \le 0.05$; $**P \le 0.01$; $***P \le 0.001$.

658

Figure 3. *RNF213* p.(Cys4177Arg) mutation: identification and functional assessment.

(A) Top left: *RNF213*-gene schematic representation (exons (black), mutation-containing

exon-47 (red)) and domain-organization model of the corresponding protein, showing the

- 662 identified mutation. CTD, C-terminal domain. Top right: Sanger electrophoregram showing
- the heterozygous *RNF213* mutation c.12529T>C, p.(Cys4177Arg) (arrow). Bottom left:
- 664 Evolutionary conservation of RNF213-protein amino-acid Cys4177 in different species.
- Bottom right: 3D structure of mouse rnf213 (6TAX in the Protein Data Bank) Cys4171
- 666 corresponding to human-RNF213 Cys4177 in red. The E3 module includes: back (orange),
- 667 RING (green), shell (yellow) and core (light yellow) subdomains. (**B**) RNF213-protein
- quantification in patient 1's (P1) and 2's (P2) dermal fibroblasts (independent skin biopsies

- (SB1) and (SB2)) and two healthy controls. (C) Cycloheximide-assay assessment of RNF213
- 670 p.(Cys4177Arg)-mutation impact on protein stability after transient mutated-protein
- expression in HEK293T cells (P = 0.023). (**D**) *RNF213*-mutation impact on NF-κB activity.
- HEK293T cells were transfected with 50 or 200 ng of the WT or C4177R-mutant RNF213
- 673 constructs or the pmaxGFP construct (mock) as control, and an NF-κB reporter construct (100
- ng). (**B**, **C**, **D**) Two-tailed *P* values were determined in unpaired *t*-tests of means \pm SD. ns: not
- 675 significant; $*P \le 0.05$; $***P \le 0.001$.
- 676

Figure 4. Signaling pathways inferred from networks of proteins interacting with

- 678 RNF213. (A) Immunoprecipitation-assay identification of RNF213 partners in immortalized
- B cells and native HEK293T cells followed by NanoLC MS/MS. Proteins are grouped into
- clusters based on their similarities (networks of enriched terms are represented as pie charts,
- with pies color-coded based on cell type (red: HEK293T cells, blue: immortalized B cells);
- 682 pie size is proportional to the total number of hits that fall into that specific term). Edge
- thickness between nodes represents the number of RNF213-interacting proteins shared by
- both pathways. Colored halos, which regroup closely related pathways, include the "cytokine-
- mediated signaling pathway" highlighted in bold. (**B**) List of protein partners of RNF213
- identified under the enriched term "Cytokine-mediated signaling pathway". Red: HEK293T
- cells; blue: immortalized B cells. **C.** CYLD-protein quantification in HEK293T transfected
- with WT or C4177R-mutant pRNF213 constructs or the pmaxGFP construct (mock control).
- NT: not transfected. Two-tailed P values were determined with unpaired t-tests of means \pm
- 690 SD of five independent experiments. ** $P \le 0.01$; *** $P \le 0.001$.
- 691

Figure E1. Skin biopsy. (A) Skin biopsy of urticarial lesions from patient (P) 1's back
showing a minor infiltrate of small lymphocytes with rare neutrophils (arrowheads)
surrounding small capillaries in the upper dermis and scattered nuclear debris interspersed
with normal epidermis. (B) The infiltrate was predominantly comprised of CD3+ T cells,
mixed with CD4+ helper and CD8+ cytotoxic T cells, with scattered FOXP3+ regulatory T
cells and cytotoxic effectors (GrzB: Granzyme B, arrowheads). Scale bar: 100 µm.


Figure E2. Laboratory parameters and plasma cytokine measurements. (A) P1's and P2's laboratory findings. Abs: antibodies; NA: not available. (B) ELISA-assessed plasmacytokine levels of patients P1 (red circle), P2 (red up-pointing triangle), P3 (red downpointing triangle) and P4 (red square) and 10 healthy donors (HD) in scatter dot plots with median. (C) IL-6 (ELISA) in the supernatants of P1's (n = 2) and P2's (n = 2) and 2 healthy controls' untreated fibroblasts. A & B: means \pm standard deviation.

- Figure E3. Enrichment analyses of differentially expressed genes (DEGs) expressed in
 patient (P) 1's and 2's monocytes. (A) Top 10 enriched terms listed for up-regulated genes.
 (B) Fold change (FC) of the top 20 up-regulated genes expressed in P1 and P2. Up-regulated
 genes associated with sepsis are in red. (C) Top: Top 10 enriched terms listed for downregulated genes. Bottom: Heatmap of enriched terms across the list of P1's and P2's downregulated genes, colored by *P*-values.
- 712

705

Figure E4. Linkage analysis and whole-exome sequencing of patients (P) identifying the 713 RNF213 c.12529T>C, p.(Cys4177Arg) mutation. (A) Linkage-analysis results of 14 family 714 715 members (8 affected and 6 unaffected) expressed in centimorgans (cM). A genome-wide 716 significant logarithm of the odds (LOD) score was obtained for a single 3.3-Mb region located on chromosome 17 (chr17: 76141133–79461642; hg19 genome assembly). (**B**) P1's and P2's 717 sequence variations identified by whole-exome sequencing and stepwise-elimination process 718 to identify the pathogenic sequence variation. (C) The 8 rare P1- and P2-shared variations 719 located in the significant LOD-score chromosome region. (D) P1's and P2's exome-720 sequencing data. Visualization using Integrative Genomics Viewer (IGV) of the RNF213 721 c.12529T>C, p.(Cys4177Arg) mutation. 722 723

724	Figure E5. In vitro study of RNF213 transcripts and protein. (A) RNF213-mRNA relative
725	expressions in dermal fibroblasts from patient (P) 1's and 2's skin biopsies (SB1 and SB2)
726	and two healthy controls (Ctr). (B) Immunoblot analysis of RNF213 and α -tubulin (as loading
727	control) in P1's and P2's SB1 and SB2 dermal fibroblasts and a Ctr. (C) Immunoblot analysis
728	of the stability of wild-type (WT) and mutated (C4177R) RNF213 proteins expressed in
729	HEK293T cells and evaluated in the cycloheximide (CHX) assay (100 μ g/ml).
730	
731	Figure E6. RNF213–cell-protein interactions identified by immunoprecipitation (IP)
732	followed by NanoLC MS/MS. (A) Venn diagram of proteins interacting with RNF213 in
733	immortalized B cells and in HEK293T cells. (B) Immunoblot analysis of RNF213 and CYLD
734	after RNF213 immunoprecipitation (IP) of HEK293T cells transiently expressing the wild-
735	type (WT) or mutated (C4177R) RNF213 protein.
736	
737	Table E1. RNA-Seq analysis data from P1's and P2's monocytes.
738	
739	Table E2. Proteomics data from immortalized B cells and HEK293T and obtained after
740	RNF213 immunoprecipitation followed by NanoLC MS/MS.
741	





P1



P2

Patient	P1	P2	P3	P4	P5	P6
Age at onset (years)	12	1	5	0.5	20	14
Age at evaluation (years)	55	56	50	31	27	23
Urticarial lesions	yes	yes	yes	yes	yes	yes
Duration of flares	Continuous, winter aggravation	Several months, winter aggravation	Continuous, winter aggravation	Continuous, winter aggravation	5-7 days, in autumn/winter	2-3 weeks, in winter
Localisation	Face, back, cleavage, arms, legs	Arms, buttock	Back, arms, buttock	Arms, buttock, legs (thighs), ears	Arms, legs (calves, knees)	Back, legs) (calves, knees)

Figure 1








Figure 2















	P1	P2	P3	P4	P5	P6	Normal range
Hemoglobin (g/dl)	13.2	13.8	15.8	14.2	12.8	14.0	Females 11.5–17.8 Males 3.0–18.0
Leukocytes (G/I)	3.1	6.4	4.1	3.5	8.4	5.7	4.0–10.0
Platelets (G/I)	231	269	240	293	243	283	150–400
Total lymphocytes (G/I)	0.6	2.3	1.2	0.95	1.2	2.4	1.0-4.0
CD4+ (cells/µl)	167	1347	NA	NA	NA	NA	475–1050
CD8+ (cells/µl)	167	567	NA	NA	NA	NA	185–570
CD19+ (cells/µl)	79	226	NA	NA	NA	NA	50–150
Neutrophils (G/I)	2.0	3.3	2.3	2.2	6.6	2.7	1.5–7.0
Monocytes (G/I)	0.37	0.6	0.5	0.3	0.47	0.48	0.2–1.0
Eosinophils (G/I)	0.069	0.2	0.078	0.11	0.15	0.057	0.02–0.6
Basophils (G/I)	0.050	0	0.029	0.021	0.017	0.052	<0.11
CRP (mg/l)	2.5	2.5	2.2	0.6	2.6	0.9	<5.0
ESR (mm/h)	15	18	16	5	9	4	Females <19 Males <11
SAA (mg/l)	15.6	9.4	7.7	<6.4	<6.4	<6.4	<6.4
Total complement – CH50 (U/ml)	57	>60	>60	48	>60	>60	>32
C3 (g/l)	1.20	1.20	1.40	0.90	1.50	1.20	0.90–1.80
C4 (g/l)	0.15	0.22	0.17	0.15	0.17	0.15	0.10–0.40
Ferritin (ng/ml)	292	192	1323	216	22	152	Females 15–150 Males 30–400
LDH (U/I)	213	211	229	151	296	193	<250
lgA (g/l)	1.33	2.00	4.29	2.84	1.70	2.55	0.70–4.00
lgG (g/l)	15.96	13.62	15.53	15.16	12.12	13.98	7.00–16.00
lgM (g/l)	0.37	0.33	0.42	0.77	0.51	1.54	0.40–2.30
lgD (mg/l)	<13.00	<13.00	30.40	16.10	48.60	38.00	<132.10
lgE (UI/mI)	13.10	66.80	288.00	118.00	329.00	65.10	<114.00
Serum Tryptase (µg/l)	4.8	3.2	3.6	10.7	2.6	1.8	<11.4
Serum Calprotectin (mg/l)			NA	NA		NA	<0.76
Antinuclear Abs aspect		320 homogeneous and speckled	<80	160 speckled	80 homogeneous and speckled		<80
dsDNA Abs	Equivocable	Negative	NA	Negative	NA	NA	
ENA Abs panel	Negative	SSB/La positive	NA	Negative	NA	NA	



Up-regulated genes

Signaling pathways: top 10	Log ₁₀ (P)
Positive regulation of cell migration	-9.83
Myeloid leukocyte activation	-9.17
Response to bacterium	-9.16
Myeloid cell differentiation	-9.16
Response to growth factor	-8.70
Positive regulation of response to external stimulus	-7.69
Positive regulation of defense response	-7.54
Regulation of MAPK cascade	-7.47
Regulation of neuron differentiation	-7.32
Positive regulation of cell adhesion	-7.13

P1		P2	P2		
Gene	FC	Gene	FC		
OLFM4	263.09	CLLU1OS	341.67		
LINC02470	90.44	TREML4	74.44		
TREML4	77.43	HSPB7	39.3		
RETN	21.17	BIRC7	29.16		
CEACAM8	14.27	HTRA3	18.84		
CD177	13.55	ULBP2	11.3		
BPI	11.32	ADGRG1	10.55		
ANXA3	10.82	CX3CR1	9.85		
LCN2	9.96	NME8	9.42		
IL6	9.52	S100B	9.05		
STON2	9.12	GAL	8.38		
PGLYRP1	8.74	LGR6	8.31		
LTF	8.38	SLC22A23	8.21		
GPRC5D-		GPRC5D-			
AS1	7.83	AS1	8.2		
HSPB7	7.83	CHIT1	7.91		
CAMP	7.08	GALNT14	7.61		
HPGD	6.79	FCRL6	7.53		
GAL	6.76	TLN2	7.4		
MMP8	6.65	NRIR	7.17		
ARG1	6.65	MYEOV	6.99		

С

Α

Down-regulated genes

Signaling pathways: top 10	Log ₁₀ (P)
Ribosome, cytoplasmic	-59.55
T-cell activation	-23.27
Hematopoietic cell lineage	-12.83
Adaptive immune response	-12.49
Alpha-beta T-cell activation	-11.20
T-cell selection	-9.27
Antigen receptor-mediated signaling pathway	-8.65
Ribosome assembly	-8.49
Leukocyte migration	-7.45
Lymphocyte costimulation	-6.53

Signaling pathways (down-regulated genes)






Figure E3

В

Up-regulated genes







С -


D

Α

Variation	Genotype	gnomAD	gnomAD Europe
DNAH17 (NM_173628) Exon 42, c.6462C>T p.(Ala2154Ala)	heterozygous	1718/278058	1293/127052 (1.02%)
<i>DNAH17</i> (NM_173628) Exon 26, c.4042C>T p.(Arg1348Cys)	heterozygous	573/280614	498/128386 (0.39%)
USP36 (NM_025090) Exon 4, c.318C>A p.(Pro106Pro)	heterozygous	3117/282174	1878/128830 (1.46%)
GAA (NM_000152) Exon 4, c.858+5insGCAGCGG	homozygous	181917/274012 †	90918/123654 (73.5%)
<i>RNF213</i> (NM_001256071) Exon 47, c.12529T>C p.(Cys4177Arg)	heterozygous	0	0
<i>ENTHD2</i> (NM_144679) Exon 6, c.437G>T p.(Gly146Val)	heterozygous	2043/256456	1399/117278 (1.19%)
<i>SLC38A10</i> (NM_138570) Exon 14, c.2284_*1del	heterozygous	9488/241908	3049/114298 (2.67%)
<i>SLC38A10</i> (NM_001037984) Exon 11, c.1146C>T p.(Val382Val)	heterozygous	2385/275134	1514/124790 (1.21%)

В


[†] Frequent variation (different annotations).




RNF213

RNF213 c.12529T>C , p.(Cys4177Arg)


Figure E4












В



Whole-cell lysates




Figure E6